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decision analytic model was developed to estimate clinical failure
by studying the resistance mechanisms of three common CAP
pathogens, S.pneumoniae, H.inﬂuenzae and the atypical
pathogens. It was estimated that in most cases 95% of resistant
pathogens would result in clinical failure. Country-speciﬁc resis-
tance rates for moxiﬂoxacin, macrolides, beta-lactams and doxy-
cycline were obtained from surveillance studies. Multi-drug
resistance was estimated using US multi-drug resistance rates.
Treatment algorithms were partially based on CAP treatment
guidelines for out-patients of the Fine risk categories, I to III,
focusing on mono-therapy. Patients could receive up to two treat-
ments in the community and one hospitalisation. The outcomes
evaluated were clinical failure avoided, hospitalisations avoided
and second-line treatments avoided. Resource use and costs were
obtained from the literature. Expert opinion was used exten-
sively to validate the clinical assumptions. RESULTS: Moxi-
ﬂoxacin dominated all other treatments in France and the US
and roxithromycin and cefuroxim strategies in Germany. Clini-
cal failure rates for moxiﬂoxacin and macrolide strategies were
5.3% and 47.3% in France, 5.2% and 16.8% in Germany and
5.2% and 23.6% the US respectively. In Germany compared to
a strategy of amoxicillin followed by roxithromycin, moxi-
ﬂoxacin had an incremental cost-effectiveness of €1 per clinical
failure avoided, but prevented 9646 clinical failures and 918 
hospitalisations per 100,000 patients. CONCLUSIONS:
Antimicrobial resistance has a signiﬁcant impact on the cost-
effectiveness of empirical treatment of CAP. The ﬁrst-line use of
moxiﬂoxacin in CAP is a cost-effective strategy for all levels of
resistance.
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OBJECTIVES: To estimate the cost-effectiveness of a systematic
Chlamydia trachomatis (CT) screening program including
partner treatment for The Netherlands using a dynamic
approach. METHODS: Data on infection prevalence, participa-
tion rates and sexual behaviour were obtained from a large pilot
study conducted in The Netherlands. We developed a dynamic
SIS (Susceptible-Infected-Susceptible) model, which is widely
used in exploring the transmission dynamics of infectious dis-
eases, to estimate the impact of screening men and women on
the incidence and prevalence of CT in the population. Subse-
quently, a progression-of-disease tree was used to calculate the
complications averted by the screening program. Cost-effective-
ness is expressed as the net costs per major outcome averted
(MOA). We compared doing nothing both with a one-off screen-
ing program and with screening on various time intervals.
RESULTS: Compared to do-nothing the one-off screening
program is estimated to cost €373 per MOA. However, restrict-
ing the screening to women only the program is estimated to save
costs. Even though screening on various time intervals adverts
more serious complications, this is less cost effective as the
screening related costs increase relatively more (e.g. bi-annual
screening is estimated to cost €3200 per MOA compared to do-
nothing). CONCLUSION: Our cost-effectiveness analysis shows
that society has net to pay for the prevention of CT complica-
tions. A one-off screening program is however more cost-
effective than screening on various time intervals. One could
argue that €373 per MOA, for the one-off screening program, is
an acceptable cost-effectiveness. A screening program consisting
of screening women only should always be adopted from a phar-
macoeconomic point of view.
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OBJECTIVE: Compare the total costs of antifungal therapy—
lipid formulation of Amphotericin B (LAB), voriconazole (VCZ)
and caspofungin (CAS)—as empirical treatment in Brazilian
institutions/patients with high risk of infection by ﬂuconazole-
resistant Candida species. METHODS: A Brazilian analytical
model was constructed using the recommended protocols for
resistant Candida infections in a 60-kg hypothetic patient and
21 days of treatment. The analysis perspective was from the
third-part payers. Drug and device prices were retail prices (data-
base: April/2005) including taxes. The daily impatiens values
used (without diagnostic testes and procedures) were obtained
from hospitalar consultants (average of costs from medium-level
hospitals in Sao Paulo). The studied scenarios were: 1) continu-
ous use of intravenous therapy in full-time impatient condition;
2) switch from IV to oral with voriconazol in full-time impatient
condition; and 3) switch from IV to oral with voriconazol and
early discharge. RESULTS: The cumulative cost for LAB was
R$81,080.37/US$32,432.15 and for CAS was R$ 50,697.38/
US$20,278.95, without changes in all scenarios. Cumulative cost
of VCZ has changed in each scenario and was R$38,382.34/
US$15,352.94, R$26,991.93/US$10,796.77 and R$23,856.44/
US$9542.58 for the scenarios 1, 2, and 3, respectively. CON-
CLUSION: In high risk Candida-resistant scenario, VCZ has 
the lower cumulative cost than CAS and LAB (scenario 1). If 
the clinical situation allows the use of oral formulation, the
advantage of VCZ increases signiﬁcantly (scenario 2), mainly if
the clinical status of patients permits discharge (scenario 3).
Moreover, the oral and/or home treatment could reduce the risk
of nosocomial infection, morbidity/mortality for immunocom-
promised patients and improve the QoL, but we couldn’t
measure these impacts because of lack of epidemiologic data in
Brazil.
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